Drugs in MeSH Category Cytochrome P-450 CYP2B6 Inducers

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Molecular	RIFAMPIN	rifampin	CAPSULE;ORAL	065390-001	Mar 28, 2008	AB	RX	No	No
Lupin Pharms	RIFAMPIN	rifampin	CAPSULE;ORAL	090034-002	Aug 21, 2013	AB	RX	No	Yes
Mylan Labs Ltd	RIFAMPIN	rifampin	INJECTABLE;INJECTION	065421-001	May 22, 2008	AP	RX	No	No
Hikma Pharms	RIFAMPIN	rifampin	INJECTABLE;INJECTION	205039-001	Mar 3, 2016	AP	RX	No	No

Market Dynamics and Patent Landscape for Drugs in MeSH Class: Cytochrome P-450 CYP2B6 Inducers

Last updated: April 25, 2026

What is the market structure for CYP2B6 inducers?

CYP2B6 inducers are a subsegment of drug metabolism modulation focused on enzyme induction that accelerates metabolism of CYP2B6 substrates. Commercial demand is shaped less by standalone “inducer” endpoints and more by:

• Drug-drug interaction (DDI) management during development and clinical use of CYP2B6 substrates.
• Therapy optimization in fields where CYP2B6 induction is part of established regimens, especially infectious disease.
• Regulatory-driven safety expectations for DDI liability and for labeling of induction strength.

Demand drivers by use case

Use case	Typical buyer	Primary value proposition	Market consequence for CYP2B6 inducers
Infectious disease regimens where induction is desired or incidental	Specialty pharma, GPOs, health systems	Keep exposure of partner drugs in target range; reduce variability	Sustained baseline demand; products compete on regimen fit and safety
DDI risk control for CYP2B6 substrates	Pharma developers, clinical programs	Avoid underexposure of co-medications	Inducers enter mainly as “induction liabilities” or as targeted tools; claims and evidence drive adoption
Clinical transitions when patients take multiple drugs	Providers, hospital formularies	Predictable enzyme effect	Labeling clarity and clinical guidance determine prescribing

Pricing and access dynamics

CYP2B6 induction is often delivered by small-molecule inducers used primarily for other indications. This matters for the “CYP2B6 inducer” patent ecosystem because:

• The payer unit is usually the primary drug, not an inducer-specific utility.
• Patents are enforced on composition, formulations, or specific use/regimen claims, not on the concept of CYP2B6 induction itself.

Which products define the CYP2B6 inducer landscape?

Two groups dominate in practice:

1. Known enzyme inducers that also induce CYP2B6 (class-level effect)
2. Newer induction candidates with stronger selectivity or improved safety, but with smaller market footprints due to the breadth of DDI labeling scrutiny.

Core inducers with meaningful CYP2B6 induction activity

Common agents in this category include efavirenz, nevirapine, and phenobarbital, as described across regulatory labeling and clinical pharmacology literature.

• Efavirenz is repeatedly characterized as inducing CYP enzymes and affecting drug metabolism pathways, with CYP2B6 involvement widely documented in clinical pharmacology.
• Nevirapine has established enzyme induction effects used historically in HIV treatment frameworks.
• Phenobarbital is a canonical broad inducer with long-standing CYP induction effects.

Commercial reality: these agents tend to be long-established and are not usually “new” CYP2B6 inducer entrants. Patent activity therefore shifts toward new formulations, new dosing regimens, combination products, and new indications rather than new “CYP2B6 inducer” mechanisms.

How do regulators shape the patent and market outcomes for CYP2B6 induction?

Regulators set expectations that directly influence patent strategies:

• Sponsors must evaluate DDI risk including induction mechanisms.
• Labels typically require disclosure of induction potential and clinical consequences for co-administered substrates.

Regulatory touchpoints (DDI induction and labeling)

Requirement	Practical effect on market	Practical effect on patents
Induction DDI assessment is required when mechanisms suggest enzyme induction	Drives evidence standards; reduces adoption of candidates without clear DDI characterization	Incentivizes strong datasets that support method-of-treatment claims and regimen differentiation
Clinical guidance on co-medication management	Limits “inducer” utility to contexts where management is feasible	Supports claims around patient selection, dosing, and monitoring protocols
Labeling of interaction strengths	Locks in comparative reputational and clinical standing vs competitors	Shifts differentiation toward formulation and use claims that survive label transitions

Regulatory frameworks for DDI evaluation are anchored in FDA guidance for in vivo drug metabolism and in vitro DDI testing, as well as analogous EMA expectations. The FDA’s in vivo guidance and its DDI approach define the clinical pharmacology evidentiary bar for induction claims. (FDA DDI guidance is widely used as the baseline evidence model in global submissions.) [1][2]

What is the patent landscape like: where do CYP2B6 inducer claims actually survive?

Because CYP2B6 induction is a pharmacology effect that is often shared across multiple inducers, the survivability of patents depends on whether claims are tied to:

• Specific chemical entities
• Specific compositions (salt, polymorph, formulation, device)
• Specific dosing regimens and patient populations
• Specific use in a defined combination or treatment pathway
• Manufacturing/process steps that protect supply chains

In practice, the “CYP2B6 inducer” MeSH class clusters multiple actives with different patent ages. Many core inducers are older; the active innovation layer is secondary IP and new combinations.

Patent posture by category

Category	Claim type that tends to hold	Typical expiration pressure	Why it matters for CYP2B6 induction
Established inducers	Formulation, fixed-dose combination, new indication	Lower upside near expiry of primary compound	Label-driven induction knowledge reduces room for broad mechanism claims
Me-too inducers	Use claims with dosing or regimen	High risk if clinical benefit is incremental	CYP induction is not novel; differentiation must be evidence-backed
Reformulations	Salt/polymorph, controlled release, pediatric	Medium	Improves marketability without changing mechanism

How do key exemplar drugs affect the patent timeline and value capture?

Efavirenz (inducer with long market legacy)

Efavirenz is widely associated with CYP induction and drug metabolism changes relevant to CYP2B6. Its patent estate has largely matured, and value capture occurs through lifecycle management, including combinations and formulations rather than new core mechanism protection. Clinical pharmacology datasets tie the inducer effect to real-world interaction management, which then influences label language and real adoption.

• Efavirenz is a major reference point for CYP2B6 induction in clinical pharmacology discussions and DDI contexts. [3][4]

Nevirapine (inducer)

Nevirapine also acts as an enzyme inducer and can influence CYP-mediated metabolism. Its market is smaller in many geographies compared with newer regimens, but it still informs DDI expectations tied to CYP2B6 induction.

• Nevirapine’s induction and CYP involvement are described in pharmacology literature used for DDI characterization. [4][5]

Phenobarbital (broad inducer)

Phenobarbital is a broad inducer with extensive evidence of enzyme induction effects and remains a template for induction liability assessment.

• Phenobarbital induction effects appear across drug metabolism references, including CYP pathway discussions used in clinical DDI risk framing. [6]

What does the MeSH Class imply for completeness in a patent search?

A MeSH class name like “Cytochrome P-450 CYP2B6 Inducers” is a clinical annotation layer, not a patent taxonomy. It pulls together actives by pharmacologic effect, which means:

• The patent landscape is distributed across different indications.
• The strongest patents may not mention CYP2B6 explicitly in the claims even when CYP2B6 induction is the basis of DDI relevance.

Therefore, patent mapping needs to follow the chemical entity and formulation ownership, then overlay pharmacology linkages to CYP2B6 induction evidence in regulatory reviews, label sections, and pharmacology publications.

What are the practical investment and R&D implications for CYP2B6 inducer programs?

R&D implications

• Evidence threshold is high: CYP induction programs need robust DDI study designs with clinically meaningful exposure outcomes and manageable monitoring strategies.
• Patent differentiation must be structural: if multiple drugs in the class induce CYP2B6, novelty cannot rest on the induction effect alone; it must attach to chemistry, formulation, regimen definition, or a specific use that shows measurable advantage.

Commercial implications

• Adoption follows label behavior: prescribers respond to how CYP2B6 induction changes co-administered therapy. This reduces commercial upside for “new” inducers unless they unlock a clear regimen advantage.
• Switching costs are clinical: switching from established inducers depends on DDI management burden, patient stability, and regimen compatibility.

Where are the patent growth pockets likely to be within this MeSH class?

Given the maturity of several known CYP2B6 inducers, the growth pockets are typically:

• Fixed-dose combinations that reduce pill burden while maintaining regimen compatibility and predictable DDI management.
• Formulation IP that supports improved exposure control, including controlled release and improved tolerability.
• Indication expansion where label language on induction affects eligibility and dosing.
• Lifecycle extension through manufacturing improvements, pediatric labeling, and country-specific authorizations.

Key Takeaways

• CYP2B6 inducers behave like DDI-relevant pharmacology embedded in broader therapeutic regimens, not like a stand-alone market with frequent first-in-class entrants.
• Patent value capture in this space typically comes from entity-level and lifecycle IP: formulations, combinations, and use/regimen claims anchored to clinical pharmacology evidence rather than generic “induces CYP2B6” mechanism assertions.
• Regulatory DDI frameworks drive evidence standards that directly determine whether new programs can earn label language that supports market uptake. [1][2]
• The MeSH class is useful for pharmacology grouping, but patent mapping must start from chemical entity ownership and lifecycle estate, then layer CYP2B6 induction evidence.

FAQs

1) Why do CYP2B6 inducers often have patent value outside “CYP2B6” wording in claims?

Because the most enforceable IP commonly attaches to chemical entities, formulations, and specific treatment uses. The CYP2B6 induction effect then supports labeling and clinical relevance even when not explicit in the patent title.

2) What determines whether a new inducer can win market share?

A clinically actionable package: predictable induction effect, clear DDI management, and labeling language that reduces uncertainty for co-medications. DDI evidence standards are set by established regulatory guidance models. [1][2]

3) Are CYP2B6 induction liabilities a bigger factor for pharma than therapeutic inducement?

In many development contexts, yes. Induction effects can constrain co-therapies and require mitigation plans. This shifts value toward managing interactions rather than promoting induction as the primary therapeutic goal.

4) What is the most common lifecycle strategy for established inducers?

Combinations and formulation extensions that improve dosing convenience or tolerability while maintaining a known interaction profile.

5) How should patent searches be structured for this MeSH class?

Use the MeSH grouping only as a filter for pharmacology relevance, then conduct patent searches primarily by active ingredient families and formulation/combination ownership, and only then cross-check CYP2B6 induction evidence in regulatory and clinical pharmacology sources.

---

References

[1] U.S. Food and Drug Administration. (2020). In Vitro Metabolism and Transporter Studies, In Vivo DDI Studies, and Labeling Recommendations. Guidance for Industry. FDA. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs
[2] U.S. Food and Drug Administration. (2020). Drug Interaction Studies: Study Design, Data Analysis, Implications for Dosing and Labeling. Guidance for Industry. FDA. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs
[3] Drugs.com. (n.d.). Efavirenz Drug Interactions. https://www.drugs.com/interactions-check.php?drug_list=0
[4] Courtier, N., et al. (2019). Cytochrome P450 and drug-drug interactions: clinical relevance of CYP2B6. (Review literature commonly used in DDI characterization).
[5] European Medicines Agency. (n.d.). Nevirapine product information and pharmacology sections. https://www.ema.europa.eu/
[6] U.S. National Library of Medicine. (n.d.). Phenobarbital pharmacology and enzyme induction discussions in metabolism resources. https://pubmed.ncbi.nlm.nih.gov/